Skip to main navigation
  • About Us
    • Our Living Values
    • Senior Management
    • Board of Directors
    • Collaborations
    • Corporate Compliance & Ethics
    • Contact Us
  • Products
    • MARGENZA®
  • Pipeline
    • MGC018 (B7-H3)
    • Enoblituzumab (anti-B7-H3)
    • Lorigerlimab (PD-1 × CTLA-4)
    • Tebotelimab (PD-1 × LAG-3)
    • IMGC936 (ADAM9)
    • MGD024 (CD123 × CD3)
    • Retifanlimab (PD-1)
    • MGD014 (HIV × CD3)
  • Platforms
    • DART® and TRIDENT®
    • Fc Optimization
  • Patients
    • Clinical Trials
    • Expanded Access
  • Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Senior Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Quarterly Results
      • Key Metrics
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
    • Investor FAQs
    • Publications
    • Contact Investor Relations
  • Careers at Macrogenics
    • Current Openings
    • Employee Benefits

Committee Composition

Shareholder Tools


  • Facebook
  • LinkedIn
  • Twitter
  • RSS

Breadcrumb

Home Investors corporate governance Committee Composition

Committee Composition

Independent Director Audit Committee Nominating and Governance Committee Compensation Committee Science and Technology Committee
Karen Ferrante, M.D. Independent Director Nominating and Governance Committee Compensation Committee Science and Technology Committee
William Heiden Independent Director Audit Committee
Edward Hurwitz Independent Director Nominating and Governance Committee Science and Technology Committee
Scott Jackson Independent Director Audit Committee Compensation Committee
Meenu Chhabra Karson Independent Director Audit Committee
Scott Koenig, M.D., Ph.D.
Margaret A. Liu, M.D., D.Sc.hc, M.D.hc Independent Director Science and Technology Committee
Federica “Freddi” O’Brien Independent Director Audit Committee
Jay Siegel M.D. Independent Director Compensation Committee Science and Technology Committee
David Stump, M.D. Independent Director Nominating and Governance Committee Compensation Committee Science and Technology Committee
= Independent Director = Chairperson = Member = Chairman of the Board
    • About Us
    • Our Living Values
    • Senior Management
    • Board of Directors
    • Collaborations
    • Products
    • MARGENZA™
    • Pipeline
    • MGC018 (B7-H3)
    • Enoblituzumab (anti-B7-H3)
    • Lorigerlimab (PD-1 × CTLA-4)
    • Tebotelimab (PD-1 × LAG-3)
    • IMGC936 (ADAM9)
    • Retifanlimab (PD-1)
    • MGD014 (HIV × CD3)
    • Platforms
    • DART® and TRIDENT®
    • Fc Optimization
    • Patients
    • Clinical Trials
    • Expanded Access
    • Investors
    • Footer investor menu

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • Financials & Filings
      • Stock Information
      • Investor FAQs
      • Publications
      • Contact Us
    • Careers
    • Current Openings
    • Employee Benefits
©2023 MacroGenics, Inc.
  • Contact Us
  • Site Map
  • Privacy Policy
  • Terms of Use
  • Other Notices